source
- Boehringer Ingelheim pauses Phase 1 study of oral candidate BI 3031185 after safety eventBoehringer Ingelheim has placed a Phase 1 study of its oral candidate BI 3031185 on hold after a safety event was identified. The trial, run in Japan with healthy volunteers, was assessing tolerab…
- Texas lawmaker warns Chinese biotech firms gaining early-stage advantage over U.S. industryRep. Nathaniel Moran, a Republican from Texas and member of the House Select Committee on China, told Fierce that the United States is overlooking how Chinese biotech companies are outpacing Americ…